TW202400656A - 使用ctla-4及pd-1雙特異性抗體之治療方法 - Google Patents

使用ctla-4及pd-1雙特異性抗體之治療方法 Download PDF

Info

Publication number
TW202400656A
TW202400656A TW112108310A TW112108310A TW202400656A TW 202400656 A TW202400656 A TW 202400656A TW 112108310 A TW112108310 A TW 112108310A TW 112108310 A TW112108310 A TW 112108310A TW 202400656 A TW202400656 A TW 202400656A
Authority
TW
Taiwan
Prior art keywords
amino acid
acid sequence
antigen
seq
dose
Prior art date
Application number
TW112108310A
Other languages
English (en)
Chinese (zh)
Inventor
謝爾比 蓋尼爾
迪帕 蘇巴馬尼亞
丹尼爾 J 弗里曼
宋緒陽
伊克貝爾 亞屈爾
查爾斯 費特
Original Assignee
美商麥迪紐有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商麥迪紐有限責任公司 filed Critical 美商麥迪紐有限責任公司
Publication of TW202400656A publication Critical patent/TW202400656A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW112108310A 2022-03-07 2023-03-07 使用ctla-4及pd-1雙特異性抗體之治療方法 TW202400656A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US202263317200P 2022-03-07 2022-03-07
US63/317,200 2022-03-07
US202263347748P 2022-06-01 2022-06-01
US63/347,748 2022-06-01
US202263374815P 2022-09-07 2022-09-07
US63/374,815 2022-09-07

Publications (1)

Publication Number Publication Date
TW202400656A true TW202400656A (zh) 2024-01-01

Family

ID=87936206

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112108310A TW202400656A (zh) 2022-03-07 2023-03-07 使用ctla-4及pd-1雙特異性抗體之治療方法

Country Status (9)

Country Link
US (1) US20230322928A1 (cg-RX-API-DMAC7.html)
EP (1) EP4489781A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508024A (cg-RX-API-DMAC7.html)
KR (1) KR20240153603A (cg-RX-API-DMAC7.html)
AU (1) AU2023231766A1 (cg-RX-API-DMAC7.html)
CA (1) CA3253514A1 (cg-RX-API-DMAC7.html)
IL (1) IL315307A (cg-RX-API-DMAC7.html)
TW (1) TW202400656A (cg-RX-API-DMAC7.html)
WO (1) WO2023170549A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017515859A (ja) * 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 抗pd−1抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
CN108367069B (zh) * 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
IL321475A (en) * 2016-05-06 2025-08-01 Medimmune Llc Bispecific binding proteins and their uses
JP7599205B2 (ja) * 2018-06-01 2024-12-13 アンヘレス セラピューティクス インコーポレイテッド 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
EP4008730A4 (en) * 2019-08-02 2023-09-06 Akeso Pharmaceuticals, Inc. BISPECIFIC ANTI-CTLA4-ANTI-PD-1 ANTIBODY AND ITS USES
US20230074793A1 (en) * 2021-08-06 2023-03-09 Xencor, Inc. Treatment with a bispecific antibody that binds ctla4 and pd1
TW202348788A (zh) * 2022-04-01 2023-12-16 美商藝康美國公司 協同防汙劑組成物及使用其之方法

Also Published As

Publication number Publication date
IL315307A (en) 2024-10-01
EP4489781A1 (en) 2025-01-15
KR20240153603A (ko) 2024-10-23
JP2025508024A (ja) 2025-03-21
AU2023231766A1 (en) 2024-10-17
EP4489781A4 (en) 2026-03-25
CA3253514A1 (en) 2023-09-14
WO2023170549A1 (en) 2023-09-14
US20230322928A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるfgfr2阻害剤単独または免疫刺激剤との組み合わせ
JP6783312B2 (ja) がんを処置するためのox40アゴニストおよび4−1bbアゴニストモノクローナル抗体の組み合わせ
TWI795347B (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
TWI835885B (zh) 用於癌症之組合療法
CN106456764A (zh) 用于治疗hpv阴性癌症的pdl‑1和pd‑1拮抗剂
CA2949121A1 (en) Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
KR20190015407A (ko) 재발성 소세포 폐암의 치료 방법에 사용하기 위한 항-pd-1 항체
KR20200108868A (ko) 암을 치료하기 위한 항-il-8 항체 및 항-pd-1 항체와의 조합 요법
US20240317864A1 (en) B7-h4 antibody dosing regimens
JP2020520912A (ja) 抗gitrアゴニスト抗体での癌の処置
JP2022500410A (ja) 非マイクロサテライト高不安定性/ミスマッチ修復の良好な結腸直腸がんを処置するためのpd−1アンタゴニストおよびlag3アンタゴニストの組み合わせ
TW202237081A (zh) 抗體及紫杉烷合併療法
US20230322928A1 (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
AU2022318734A1 (en) Methods for treating acute myeloid leukemia with anti-ilt3 antibodies
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
HK40117614A (en) Treatment methods using ctla-4 and pd-1 bispecific antibodies
CN118829446A (zh) 使用ctla-4和pd-1双特异性抗体的治疗方法
CA3091161C (en) B7-h4 antibody dosing regimens
US20230365691A1 (en) Use of anti-pd-1 antibody in treatment of nasopharyngeal carcinoma
KR20260013484A (ko) 암 치료에서 t 세포 인게이징 단백질의 용도
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
EA048025B1 (ru) Комбинированная терапия онкологического заболевания